ZAMBON S.P.A

Company snapshot

LA PRODUZIONE, LA PREPARAZIONE E LA VENDITA DI PRODOTTI FARMACEUTICI PER USO UMANO

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for ZAMBON S.P.A. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for ZAMBON S.P.A.

1. Jun 8, 2026 Clinical update

   ZB203L01 — Phase 3

2. Jun 8, 2026 Clinical update

   Liposomal Ciclosporin A, Liposomal Ciclosporin A — Phase 3

3. May 26, 2026 Clinical update

   CMS — Phase 3

View all clinical trial activity →

• What is ZAMBON S.P.A?

  Zambon SpA is a pharma organization headquartered in EU. Primary therapeutic focus areas include Motor fluctuations in advanced Parkinson’s disease, Non Cystic Fibrosis Bronchiectasis. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this e

• Is ZAMBON S.P.A publicly traded?

  ZAMBON S.P.A appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does ZAMBON S.P.A develop or market?

  We link 7 drug profile(s) where ZAMBON S.P.A is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/zambon-spa#company-drugs.

• What are the latest developments for ZAMBON S.P.A?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does ZAMBON S.P.A focus on?

  ZAMBON S.P.A focuses on Motor fluctuations in advanced Parkinson’s disease, Non Cystic Fibrosis Bronchiectasis based on our analysis of their pipeline programs and drug development activities.